Glenmark Pharmaceuticals Ltd. NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2132.50 4.80 (0.23%)

67.19% Gain from 52W Low

623.4K

NSE+BSE Volume

NSE 12 Sep, 2025 3:31 PM (IST)

Dividend

Glenmark Pharmaceuticals Ltd. has an upcoming dividend of ₹2.50 per share due on 15 Sep 2025 See details

Glenmark Pharmaceuticals Ltd. share price target

Glenmark Pharmaceuticals Ltd. has an average share price target of 2144. The consensus estimate represents an upside of 0.54% from the last price of 2132.50. View 11 reports from 5 analysts offering long-term price targets for Glenmark Pharmaceuticals Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	13 Sep 2025	Glenmark Pharma	Consensus Share Price Target	2132.50	2248.67	-	5.45	buy	pdf Detailed Estimates
	21 Nov 2022	Glenmark Pharma	ICICI Direct Target	2132.50	470.00	422.40 (404.85%)	Target met	Hold	pdf post cache		Broker Report Glenmark Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	19 Nov 2022	Glenmark Pharma	Prabhudas Lilladhar Target	2132.50	460.00	411.65 (418.04%)	Target met	Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	17 Nov 2022	Glenmark Pharma	Motilal Oswal	2132.50	420.00	409.85 (420.31%)	Target met	Neutral	pdf post cache		Broker Report Working on many fronts to better outlook and return ratios Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	16 Aug 2022	Glenmark Pharma	ICICI Direct	2132.50	440.00	389.25 (447.85%)	Target met	Hold	pdf post cache		Broker Report Glenmark Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2022	Glenmark Pharma	ICICI Securities Limited Reco Target	2132.50	478.00	388.80 (448.48%)	Target met	Buy	pdf post cache		Broker Report High base and weak US sales hit performance ICICI Securities Limited Glenmark Pharma’s (Glenmark) Q1FY23 performance missed our estimates. pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2022	Glenmark Pharma	Motilal Oswal	2132.50	420.00	389.25 (447.85%)	Target met	Neutral	pdf post cache		Broker Report Steady traction exhibited in DF/ROW Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	07 Jun 2022	Glenmark Pharma	Geojit BNP Paribas Reco Target	2132.50	485.00	388.45 (448.98%)	Target met	Buy	pdf post cache		Broker Report GLENMARK PHARMACEUTICALS Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Glenmark Pharma	Prabhudas Lilladhar Target	2132.50	450.00	389.10 (448.06%)	Target met	Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Glenmark Pharma	Motilal Oswal Target	2132.50	420.00	393.55 (441.86%)	Target met	Neutral	pdf post cache		Broker Report US remains a drag on overall performance Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2022	Glenmark Pharma	Prabhudas Lilladhar Target	2132.50	550.00	487.20 (337.71%)		Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar Strong revenue growth across India, EU and RoW markets: Revenue grew 14% YoY to Rs31.7bn vs our est of Rs31bn. During Q3, Ichnos entered into an exclusive licensing agreement with Almirall SA and received upfront payment of EURO20.8mn. Adjusted for this revenue growth was 7% YoY. India formulations grew strongly by 14%. US growth was flat QoQ to US$101mn. LATAM sales declined by 9% YoY due to pandemic challenges in Brazil. Robust growth in RoW of 24% YoY, aided by strong traction in Ryaltris. EU... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners